Predictive values of colon microbiota in the treatment response to colorectal cancer

The crosstalk between the colon mucosa and the microbiota represents a complex and delicate equilibrium. Gastrointestinal diseases such as inflammatory bowel disease and colorectal cancer (CRC) are associated with a state of altered microbiota composition known as dysbiosis, which seems to play a ca...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2020-09, Vol.21 (14), p.1045-1059
Main Authors: Galan-Ros, Jorge, Ramos-Arenas, Verónica, Conesa-Zamora, Pablo
Format: Article
Language:English
Subjects:
chemotherapy
dysbiosis
fecal microbiota transplantation
immune checkpoint
microbiome
prebiotics
probiotics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The crosstalk between the colon mucosa and the microbiota represents a complex and delicate equilibrium. Gastrointestinal diseases such as inflammatory bowel disease and colorectal cancer (CRC) are associated with a state of altered microbiota composition known as dysbiosis, which seems to play a causative role in some of these illnesses. Recent reports have shown that the colorectal microbiome is responsible for the response and safety to treatments against CRC, especially immunotherapy, hence opening the possibility to use bacteria as a predictive marker and also as a therapeutic agent. The review objective is to summarize updated reports about the the implication of the colorectal microbiome in the development of CRC, in treatment response and its potential as a therapeutic approach.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2020-0044